183 related articles for article (PubMed ID: 38155221)
21. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
Hayashi Y; Makino T; Sato E; Ohshima K; Nogi Y; Kanemura T; Honma K; Yamashita K; Saito T; Tanaka K; Yamamoto K; Takahashi T; Kurokawa Y; Miyata H; Nakajima K; Wada H; Morii E; Eguchi H; Doki Y
Br J Cancer; 2023 Jun; 128(12):2175-2185. PubMed ID: 37016103
[TBL] [Abstract][Full Text] [Related]
22. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
23. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
Peng H; Wu X; Zhang C; Liang Y; Cheng S; Zhang H; Shen L; Chen Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):153. PubMed ID: 38519621
[TBL] [Abstract][Full Text] [Related]
24. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
25. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
[TBL] [Abstract][Full Text] [Related]
26. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
30. Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.
Zhang Y; Li J; Yang F; Zhang X; Ren X; Wei F
J Leukoc Biol; 2022 Dec; 112(6):1591-1603. PubMed ID: 35501298
[TBL] [Abstract][Full Text] [Related]
31. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
Yao Y; Xuan H; Wang J; Gong L; Gao W
Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
[TBL] [Abstract][Full Text] [Related]
32. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
34. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma.
Guo S; Chen J; Yi X; Lu Z; Guo W
Front Immunol; 2022; 13():985051. PubMed ID: 36248853
[TBL] [Abstract][Full Text] [Related]
36. DNA damage repair-related gene signature predicts prognosis and indicates immune cell infiltration landscape in skin cutaneous melanoma.
Liang L; Mai S; Mai G; Chen Y; Liu L
Front Endocrinol (Lausanne); 2022; 13():882431. PubMed ID: 35957812
[TBL] [Abstract][Full Text] [Related]
37. Melanoma Molecular Subtypes and Development of Prognostic and Immunotherapy-Related Genetic Characteristics by Ferroptosis Gene Analysis.
Xu L; Zhang Y; Liu T; Wang L; Zhao Z; Zhang X; Li X; Wu W; Yu S
Comput Math Methods Med; 2022; 2022():2992939. PubMed ID: 35516454
[TBL] [Abstract][Full Text] [Related]
38. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
Mo Z; Liu J; Zhang J; Deng Y; Xu M; Jiang Y
Int Immunopharmacol; 2023 Nov; 124(Pt B):110973. PubMed ID: 37769536
[TBL] [Abstract][Full Text] [Related]
39. Genomic properties and clinical outcomes associated with tertiary lymphoid structures in patients with breast cancer.
Wang L; Gong S; Pang L; Zhang S; Zhang X; He W
Sci Rep; 2023 Aug; 13(1):13542. PubMed ID: 37598257
[TBL] [Abstract][Full Text] [Related]
40. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
